`__________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`__________________
`
`DR.REDDY’S LABORATORIES INC. and
` DR. REDDY’S LABORATORIES LTD.,
`Petitioners,
`
`v.
`
`MERCK SHARP & DOHME CORP.,
`Patent Owner.
`__________________
`
`Case No. IPR2020-01060
`U.S. Patent No. 7,326,708
`__________________
`
`MANDATORY NOTICES OF
`PATENT OWNER MERCK SHARP & DOHME CORP.
`
`
`
`
`
`
`
`
`
`
`Pursuant to 37 C.F.R. § 42.8(a)(2), Patent Owner Merck Sharp & Dohme
`
`Case No. IPR2020-01060
`U.S. Patent No. 7,326,708
`
`(“Merck”) submits the following mandatory notices:
`
`I.
`
`Real Parties in Interest, 37 C.F.R. § 42.8(b)(1)
`
`Merck is the owner and assignee of U.S. Patent No. 7,328,708 (“the ’708
`
`patent”). Merck is a wholly owned subsidiary of Merck & Co., Inc. Merck & Co.,
`
`Inc. has no parent corporation, and no publicly held corporation owns 10% or more
`
`of its stock.
`
`II. Related Matters, 37 C.F.R. § 42.8(b)(2)
`
`The ’708 patent is currently the subject of the following litigations:
`
` In re Sitagliptin (’708 & ’921) Patent Litigation, Case No. 1:19-md-02902-
`RGA (D. Del.)
`
` Merck Sharp & Dohme Corp. v. Alvogen Pine Brook LLC f/k/a Alvogen Pine
`Brook, Inc. and Alvogen Malta Operations Ltd., Case No. 1:19-cv-00310-
`RGA (D. Del.);
`
` Merck Sharp & Dohme Corp. v. Anchen Pharmaceuticals, Inc. and Par
`Pharmaceutical, Inc., Case No. 1:19-cv-00311-RGA (D. Del.);
`
` Merck Sharp & Dohme Corp. v. Sandoz Inc., Case No. 1:19-cv-00312-RGA
`(D. Del.);
`
` Merck Sharp & Dohme Corp. v. Apotex Inc., and Apotex Corp., Case No.
`1:19-cv-00313-RGA (D. Del.);
`
` Merck Sharp & Dohme Corp. v. Apotex Inc., and Apotex Corp., Case No.
`1:20-cv-00749-RGA (D. Del.)
`
` Merck Sharp & Dohme Corp. v. Zydus Pharmaceuticals (USA) Inc. and
`Cadila Healthcare Ltd., Case No. 1:19-cv-00314 (D. Del.);
`
`2
`
`
`
`
`
` Merck Sharp & Dohme Corp. v. Watson Laboratories, Inc. and Teva
`Pharmaceuticals USA, Inc., Case No. 1:19-cv-00317-RGA (D. Del.);
`
`Case No. IPR2020-01060
`U.S. Patent No. 7,326,708
`
` Merck Sharp & Dohme Corp. v. Teva Pharmaceuticals USA, Inc., Case No.
`1:19-cv-00318-RGA (D. Del.);
`
` Merck Sharp & Dohme Corp. v. Sun Pharmaceutical Industries Ltd., Case
`No. 1:19-cv-00319-RGA (D. Del.);
`
` Merck Sharp & Dohme Corp. v. Lupin Limited and Lupin Pharmaceuticals,
`Inc., Case No. 1:19-cv-00347-RGA (D. Del.);
`
` Merck Sharp & Dohme Corp. v. Lupin Limited and Lupin Pharmaceuticals,
`Inc., Case No. 1:20-cv-00776-RGA (D. Del.);
`
` Merck Sharp & Dohme Corp. v. Ajanta Pharma Limited and Ajanta Pharma
`USA Inc., Case No. 1:20-cv-00815-UNA (D. Del.);
`
` Merck Sharp & Dohme Corp. v. Dr. Reddy’s Laboratories Ltd. and Dr.
`Reddy’s Laboratories, Inc., Case No. 1:20-cv-00847-UNA (D. Del.);
`
` Merck Sharp & Dohme Corp. v. Mylan Pharmaceuticals Inc. and Mylan
`Inc., Case No. 1:19-cv-00101-IMK (N.D. W. Va.); and
`
` Merck Sharp & Dohme Corp. v. Mylan Pharmaceuticals Inc. and Mylan
`Inc., Case No. 1:19-cv-01489-RGA (D. Del.).
`
`The ’708 patent is currently the subject of the following administrative
`
`proceedings:
`
` Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp., IPR2020-
`00040;
`
` Teva Pharmaceuticals USA, Inc. et al v. Merck Sharp & Dohme Corp.,
`IPR2020-01045; and
`
` Sun Pharmaceutical Industries, LTD. v. Merck Sharp & Dohme Corp.,
`IPR2020-01072.
`
`3
`
`
`
`
`III. Lead & Backup Counsel, 37 C.F.R. § 42.8(b)(3)
`
`Merck designates the following attorney as lead counsel:
`
`Case No. IPR2020-01060
`U.S. Patent No. 7,326,708
`
`Stanley E. Fisher
`Reg. No. 55,820
`Williams & Connolly LLP
`725 Twelfth Street, N.W.
`Washington, DC 20005
`T: (202) 434-5000
`F: (202) 434-5029
`sfisher@wc.com
`
`Merck designates the following attorney as first backup counsel:
`
`Jessamyn S. Berniker
`Reg. No. 72,328
`Williams & Connolly LLP
`725 Twelfth Street, N.W.
`Washington, DC 20005
`T: (202) 434-5000
`F: (202) 434-5029
`jberniker@wc.com
`
`Merck designates the following attorneys as backup counsel:
`
`Bruce R. Genderson
`(Pro Hac Vice Motion to be submitted)
`WILLIAMS & CONNOLLY LLP
`725 Twelfth Street, N.W.
`Washington, DC 20005
`T: (202) 434-5000
`F: (202) 434-5029
`bgenderson@wc.com
`
`
`Alexander S. Zolan
`(Pro Hac Vice Motion to be submitted)
`WILLIAMS & CONNOLLY LLP
`
`4
`
`
`
`Case No. IPR2020-01060
`U.S. Patent No. 7,326,708
`
`725 Twelfth Street, N.W.
`Washington, DC 20005
`T: (202) 434-5208
`F: (202) 434-5029
`azolan@wc.com
`
`Elise M. Baumgarten
`(Pro Hac Vice Motion to be submitted)
`WILLIAMS & CONNOLLY LLP
`725 Twelfth Street, N.W.
`Washington, DC 20005
`T: (202) 434-5894
`F: (202) 434-5029
`ebaumgarten@wc.com
`
`
`
`
`
`Shaun P. Mahaffy
`Reg. No. 75,534
`WILLIAMS & CONNOLLY LLP
`725 Twelfth Street, N.W.
`Washington, DC 20005
`T: (202) 434-5000
`F: (202) 434-5029
`smahaffy@wc.com
`
`Anthony H. Sheh
`Reg. No. 70,576
`WILLIAMS & CONNOLLY LLP
`725 Twelfth Street, N.W.
`Washington, DC 20005
`T: (202) 434-5436
`F: (202) 434-5029
`asheh@wc.com
`
`Powers of attorney appointing these attorneys to transact all business in this
`
`proceeding on behalf of Merck have been submitted or will be submitted with this
`
`mandatory notice information.
`
`5
`
`
`
`
`IV. Service Information, 37 C.F.R. § 42.8(b)(4)
`
`Counsel for Merck submits the following service information:
`
`Case No. IPR2020-01060
`U.S. Patent No. 7,326,708
`
`
`
`Electronic mail addresses:
`
`Postal mail addresses:
`
`Telephone number:
`
`Facsimile number:
`
`
`
`sfisher@wc.com,
`bgenderson@wc.com,
`jberniker@wc.com,
`azolan@wc.com,
`ebaumgarten@wc.com,
`smahaffy@wc.com,
`asheh@wc.com,
`MerckSitagliptin@wc.com
`
`Stanley E. Fisher
`WILLIAMS & CONNOLLY LLP
`725 Twelfth Street, N.W.
`Washington, DC 20005
`
`(202) 434-5000
`
`(202) 434-5029
`
`Counsel for Merck consent to electronic service by email at
`
`sfisher@wc.com, bgenderson@wc.com, jberniker@wc.com, azolan@wc.com.
`
`ebaumgarten@wc.com, smahaffy@wc.com, asheh@wc.com, and
`
`MerckSitagliptin@wc.com.
`
`
`Date: July 1, 2020
`
`
`
`Respectfully submitted,
`
`/Stanley E. Fisher/
`Stanley E. Fisher (Reg. No. 55,820)
`Bruce R. Genderson (Pro Hac Vice)
`Jessamyn S. Berniker (Reg. No. 72,328)
`
`
`
`6
`
`
`
`
`
`
`
`Case No. IPR2020-01060
`U.S. Patent No. 7,326,708
`
`Alexander S. Zolan (Pro Hac Vice)
`Elise M. Baumgarten (Pro Hac Vice)
`Shaun P. Mahaffy (Reg. No. 75,534)
`Anthony H. Sheh (Reg. No. 70,576)
`WILLIAMS & CONNOLLY LLP
`725 Twelfth Street, N.W.
`Washington, DC 20005
`T: (202) 434-5000
`F: (202) 434-5029
`sfisher@wc.com
`bgenderson@wc.com
`jberniker@wc.com
`azolan@wc.com
`ebaumgarten@wc.com
`smahaffy@wc.com
`asheh@wc.com
`
`Counsel for Patent Owner
`Merck Sharp & Dohme Corp.
`
`
`
`7
`
`
`
`Case No. IPR2020-01060
`U.S. Patent No. 7,326,708
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6(e), the undersigned hereby certifies that a true
`
`and correct copy of the foregoing was served on July 1, 2020, by delivering a copy
`
`via electronic mail on the following attorneys of record:
`
`Russell W. Faegenburg
`Tedd W. Van Buskirk
`Michael H. Teschner
`LERNER, DAVID, LITTENBERG, KRUMHOLZ &
`MENTLIK, LLP
`20 Commerce Drive, Cranford, New
`Jersey 07016
`(908) 518-6367
`Rfaegenburg.ipr@ldlkm.com
`Tvanbuskirk@lernerdavid.com
`MTeschner.ipr@ldlkm.com
`
`
`
`/Shaun P. Mahaffy/
`Shaun P. Mahaffy
`Reg. No. 75,534
`
`
`
`
`
`
`
`
`
`
`
`
`
`8
`
`